These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 17427618)

  • 21. [Therapy of venous thromboembolism].
    Niederer A; Wuillemin WA
    Praxis (Bern 1994); 2001 Feb; 90(6):213-9. PubMed ID: 11235642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.
    Deerhake JP; Merz JC; Cooper JV; Eagle KA; Fay WP
    J Thromb Thrombolysis; 2007 Apr; 23(2):107-13. PubMed ID: 17221327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin?
    Jaff MR
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S17-21. PubMed ID: 19213061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
    Rhodes S; Bond S
    Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticoagulation management of valve replacement patients.
    Ezekowitz MD
    J Heart Valve Dis; 2002 Jan; 11 Suppl 1():S56-60. PubMed ID: 11843522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS
    Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-molecular-weight heparin in outpatient treatment of DVT.
    Yeager BF; Matheny SC
    Am Fam Physician; 1999 Feb; 59(4):945-52. PubMed ID: 10068716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
    Prandoni P; Simioni P; Pagnan A
    Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Singer DE; Albers GW; Dalen JE; Fang MC; Go AS; Halperin JL; Lip GYH; Manning WJ
    Chest; 2008 Jun; 133(6 Suppl):546S-592S. PubMed ID: 18574273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
    Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
    Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updated guidelines on outpatient anticoagulation.
    Wigle P; Hein B; Bloomfield HE; Tubb M; Doherty M
    Am Fam Physician; 2013 Apr; 87(8):556-66. PubMed ID: 23668445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.
    Kovacs MJ; Rodger M; Anderson DR; Morrow B; Kells G; Kovacs J; Boyle E; Wells PS
    Ann Intern Med; 2003 May; 138(9):714-9. PubMed ID: 12729425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticoagulants in the treatment of deep vein thrombosis.
    Merli G
    Am J Med; 2005 Aug; 118 Suppl 8A():13S-20S. PubMed ID: 16125510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
    N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.